300558 贝达药业
交易中 09-29 10:20:18
资讯
新帖
简况
贝达药业(300558.SZ)：BPI-572270胶囊获批在澳大利亚开展临床试验
智通财经 · 09-28 17:28
贝达药业(300558.SZ)：BPI-572270胶囊获批在澳大利亚开展临床试验
贝达药业：BPI-57.23万获批澳大利亚I/Ⅱ期临床
格隆汇 · 09-28 16:50
贝达药业：BPI-57.23万获批澳大利亚I/Ⅱ期临床
贝达药业（300558）9月24日主力资金净卖出6821.79万元
证券之星 · 09-28 09:24
贝达药业（300558）9月24日主力资金净卖出6821.79万元
贝达药业：公司将坚持“自主研发、战略合作、市场销售、创新生态圈”四驾马车协同发展
证券之星 · 09-24
贝达药业：公司将坚持“自主研发、战略合作、市场销售、创新生态圈”四驾马车协同发展
贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制
证券之星 · 09-24
贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制
贝达药业：2026年上半年实现营业收入19.76亿元，同比增长14.12%
证券之星 · 09-24
贝达药业：2026年上半年实现营业收入19.76亿元，同比增长14.12%
贝达药业：取得FRSW117在中国独家经销权
证券之星 · 09-24
贝达药业：取得FRSW117在中国独家经销权
贝达药业：本期计提商誉减值准备2,993.34万元
证券之星 · 09-24
贝达药业：本期计提商誉减值准备2,993.34万元
贝达药业：BK-001（VM 001）目前处于临床前阶段
证券之星 · 09-24
贝达药业：BK-001（VM 001）目前处于临床前阶段
贝达药业：BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物
证券之星 · 09-24
贝达药业：BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物
贝达药业：2025年全年研发投入达5.74亿元
证券之星 · 09-24
贝达药业：2025年全年研发投入达5.74亿元
贝达药业：BPI-460372正在开展Ⅰ期临床研究
证券之星 · 09-24
贝达药业：BPI-460372正在开展Ⅰ期临床研究
贝达药业：董事会秘书空缺期间由董事长代行
证券之星 · 09-24
贝达药业：董事会秘书空缺期间由董事长代行
贝达药业：公司持续推进产品上市后研究及联合用药探索
证券之星 · 09-24
贝达药业：公司持续推进产品上市后研究及联合用药探索
贝达药业：恩沙替尼在美国市场尚处于商业化早期阶段
证券之星 · 09-23
贝达药业：恩沙替尼在美国市场尚处于商业化早期阶段
贝达药业：本期收回的股权投资为C4 Therapeutics, Inc
证券之星 · 09-23
贝达药业：本期收回的股权投资为C4 Therapeutics, Inc
贝达药业：本期差旅费同比增幅较大
证券之星 · 09-23
贝达药业：本期差旅费同比增幅较大
贝达药业：伏罗尼布的眼科适应症由公司合作伙伴EyePoint主导开发
证券之星 · 09-23
贝达药业：伏罗尼布的眼科适应症由公司合作伙伴EyePoint主导开发
贝达药业：二季度扣非净利润环比出现波动
证券之星 · 09-23
贝达药业：二季度扣非净利润环比出现波动
贝达药业最新公告：盐酸恩沙替尼胶囊获欧洲药品管理局人用药品委员会积极意见
证券之星 · 09-20
贝达药业最新公告：盐酸恩沙替尼胶囊获欧洲药品管理局人用药品委员会积极意见
加载更多
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":49.14,"timestamp":1790648418000,"preClose":47.71,"halted":0,"volume":7524155,"delay":0,"changeRate":0.03,"floatShares":422000000,"shares":423000000,"eps":1.1045,"marketStatus":"交易中","change":1.43,"latestTime":"09-29 10:20:18","open":47.86,"high":50.88,"low":47.48,"amount":374000000,"amplitude":0.0713,"askPrice":49.14,"askSize":5,"bidPrice":49.11,"bidSize":27,"shortable":0,"etf":0,"ttmEps":1.1045,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1790652600000},"marketStatusCode":2,"adr":0,"adjPreClose":47.71,"symbolType":"stock","openAndCloseTimeList":[[1790645400000,1790652600000],[1790658000000,1790665200000]],"highLimit":52.48,"lowLimit":42.94,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423331685,"isCdr":false,"pbRate":3.05,"roa":"--","peRate":44.49072,"roe":"4.61%","epsLYR":0.73,"committee":0.694915,"marketValue":20803000000,"turnoverRate":0.0178,"status":0,"floatMarketCap":20746000000},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2670323311","title":"贝达药业(300558.SZ)：BPI-572270胶囊获批在澳大利亚开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2670323311","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670323311?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:28","pubTimestamp":1790587693,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布公告，公司全资子公司杭州景曜生物科技有限责任公司(以下简称“景曜生物”)申报的BPI-572270胶囊用于携带特定RAS突变的晚期实体瘤患者的I/Ⅱ期临床研究已获得澳大利亚人类研究伦理委员会(HumanResearch Ethics Committee，以下简称“HREC”)的审查批准，并完成澳大利亚药品管理局(简称“TGA”)临床试验备案，这是公司首款在澳大利亚获批开展临床试验的新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IBBJ","PSYK","MDTX","BMED","BK0060","IBBQ","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670095280","title":"贝达药业：BPI-57.23万获批澳大利亚I/Ⅱ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2670095280","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670095280?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:50","pubTimestamp":1790585449,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670077624","title":"贝达药业（300558）9月24日主力资金净卖出6821.79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670077624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670077624?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:24","pubTimestamp":1790558662,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，贝达药业报收于48.23元，下跌4.23%，换手率2.08%，成交量8.76万手，成交额4.29亿元。近5日资金流向一览见下表：贝达药业融资融券信息显示，融资方面，当日融资买入3225.1万元，融资偿还4631.04万元，融资净偿还1405.95万元。贝达药业主营业务：致力于新药研发和推广,以解决肺癌等恶性肿瘤治疗领域中未被满足的临床需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800002935.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669498050","title":"贝达药业：公司将坚持“自主研发、战略合作、市场销售、创新生态圈”四驾马车协同发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2669498050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669498050?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:51","pubTimestamp":1790254294,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。请问董秘，公司如何契合这一规划，使贝达药业在创新发展和年营收方面达到目标？公司将坚持\"自主研发、战略合作、市场销售、创新生态圈\"四驾马车协同发展，持续完善\"研发投入－产品商业化－收益再投入\"的良性循环机制，不断提升创新研发与产业化能力，并坚持国际化发展战略，持续推进创新药开发与商业化，推动公司长期稳定发展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400038307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669450428","title":"贝达药业：公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制","url":"https://stock-news.laohu8.com/highlight/detail?id=2669450428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669450428?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:48","pubTimestamp":1790236111,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：建议公司年报、半年报都聚焦于自身研发产品和拥有权益产品的研发进展，对于代销产品和别人家的产品少评判。贝达药业回复：您好！公司定期报告按照中国证监会及深圳证券交易所的相关披露要求编制，围绕公司主营业务、产品管线及具体经营成果进行披露。公司将持续提升定期报告披露的质量，更好地向投资者介绍和展示公司产品管线。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","399001","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669245047","title":"贝达药业：2026年上半年实现营业收入19.76亿元，同比增长14.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669245047","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669245047?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:48","pubTimestamp":1790236111,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，纵观贵公司2026年中报数据，公司9款商业化产品，为何营业收入不到同行业艾某斯1款产品的六成，净利润也不到其两成？2026年上半年，公司实现营业收入19.76亿元，同比增长14.12%；实现归属于上市公司股东的净利润3.02亿元，同比增长115.97%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023470.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669845040","title":"贝达药业：取得FRSW117在中国独家经销权","url":"https://stock-news.laohu8.com/highlight/detail?id=2669845040","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669845040?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:48","pubTimestamp":1790236109,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。2025年，公司与晟斯生物达成战略合作，并取得注射用培重组人凝血因子VIII-Fc融合蛋白在中国的独家经销权，目前FRSW117的上市申请已获受理，正处于审评阶段。晟斯生物在长效生长激素的研究领域已有布局和探索，公司将充分发挥生态圈企业的科研协同，加快推进新药的开发和产业化。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669504794","title":"贝达药业：本期计提商誉减值准备2,993.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669504794","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669504794?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:45","pubTimestamp":1790235913,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。根据企业会计准则及公司财务制度要求，公司需在各报告期末开展商誉减值测试。基于谨慎性原则，公司重新评估相关资产组的可收回金额，本期计提商誉减值准备2,993.34万元，相关会计处理符合会计准则规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669445040","title":"贝达药业：BK-001（VM 001）目前处于临床前阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669445040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669445040?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:45","pubTimestamp":1790235911,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，康万达和贝达药业合作的VM-001项目推进情况？今年是否可以申报开展临床试验？贝达药业回复：您好！公司与康万达共同开发的抗体-溶瘤病毒组合疗法BK-001（VM 001）目前处于临床前阶段，如有重大节点公司将及时公告披露。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400023067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669926450","title":"贝达药业：BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物","url":"https://stock-news.laohu8.com/highlight/detail?id=2669926450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669926450?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:42","pubTimestamp":1790235737,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。BD交易需要匹配合适的合作伙伴、合理的估值和有利的交易条件，公司高度关注BD合作机会，正在积极推进自主创新药海外权益的转让工作。BPI-572270是公司自主研发、拥有完全自主知识产权的新分子实体化合物，临床前数据显示其在活性和药代动力学特性方面具有差异化优势，具备全球化合作的条件。如有重大合作进展，公司将及时公告披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669945018","title":"贝达药业：2025年全年研发投入达5.74亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669945018","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669945018?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:42","pubTimestamp":1790235735,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。公司始终坚持创新投入，2025年全年研发投入达5.74亿元，上榜2025民营企业研发投入500家榜单；2026年上半年，公司研发投入2.31亿元。目前，公司已整合设立贝达研究院，确立了新药项目以具有临床竞争力的\"差异化\"和\"迭代升级\"为核心的立项标准，并不断完善新药项目开发的动态评估机制，集中资源，聚焦核心项目开发，提升研发投入产出的效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669902450","title":"贝达药业：BPI-460372正在开展Ⅰ期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2669902450","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669902450?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:42","pubTimestamp":1790235731,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：美国Vivace Therapeutics宣布其口服TEAD抑制剂VT3989的注册性III期临床获FDA“可启动”通知，是TEAD抑制剂类别首次推进至全球III期。请问作为全球进度第二的BPI-460372的目前进展和优势？BPI-460372是公司自主研发的口服小分子Hippo信号通路TEAD转录因子抑制剂，拟用于治疗晚期实体瘤患者，目前正在开展Ⅰ期临床研究。如有重大进展，公司将及时公开披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669450133","title":"贝达药业：董事会秘书空缺期间由董事长代行","url":"https://stock-news.laohu8.com/highlight/detail?id=2669450133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669450133?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:39","pubTimestamp":1790235554,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董事会秘书按规定多久时间内必须到位？请明确？贝达药业回复：您好！根据《上市公司董事会秘书监管规则》等相关规定，董事会秘书空缺期间由董事长代行董事会秘书职责，上市公司应当在六个月内完成董事会秘书的聘任工作。目前，公司董事会秘书职责由董事长丁列明先生代行，公司将按照相关规定完成聘任并及时履行信息披露义务。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669945093","title":"贝达药业：公司持续推进产品上市后研究及联合用药探索","url":"https://stock-news.laohu8.com/highlight/detail?id=2669945093","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669945093?lang=zh_cn&edition=full","pubTime":"2026-09-24 15:36","pubTimestamp":1790235395,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：现在很多公司都在和康方的112联用，你们不考虑吗？贝达药业回复：您好！公司持续推进产品上市后研究及联合用药探索，根据产品的治疗特点和临床需求设计和探索用药方案，如有相关合作公司将及时公开。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400022008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109425","title":"贝达药业：恩沙替尼在美国市场尚处于商业化早期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669109425?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:42","pubTimestamp":1790152933,"startTime":"0","endTime":"0","summary":"投资者提问：Xcovery上半年营业收入7,304,702.28元，营业利润-121,193,236.28元，恩莎替尼在美国市场已经获批2年，销售却异常惨淡，具体原因是什么？恩沙替尼在美国市场尚处于商业化早期阶段，产品销售放量需要时间。Xcovery同时承担海外临床研发、专利维护、合规运营等多项成本，目前公司已与第三方机构开展合作，进一步完善恩沙替尼在美国的商业化布局，未来随着销售收入的提升，财务指标将得到改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669810947","title":"贝达药业：本期收回的股权投资为C4 Therapeutics, Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2669810947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669810947?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:42","pubTimestamp":1790152930,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：收回股权投资 现金流入增加投资活动流量净额-249,974,287.96，请问具体回收那部分股权？贝达药业回复：您好！本期收回的股权投资为C4 Therapeutics, Inc.谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669109280","title":"贝达药业：本期差旅费同比增幅较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2669109280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669109280?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:39","pubTimestamp":1790152754,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：上半年差旅费用94,274,216.52，而去年同期只有41,784,185.07元，异常增长的原因是什么？， 其他费用比同期也增加50%，具体为什么费用？贝达药业回复：您好！本期差旅费同比增幅较大，主要系报告期公司多款新产品处于上市后市场导入阶段，肿瘤业务部加大全国区域学术推广布局，出差人次及频次明显提升。其他费用同比增长，主要系销售业务相关的办公费、咨询服务费等投入增加。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669490109","title":"贝达药业：伏罗尼布的眼科适应症由公司合作伙伴EyePoint主导开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669490109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669490109?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:39","pubTimestamp":1790152753,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：子公司卡南吉首个Ⅲ期临床研究 LUGANO2026年8月18号才公布数据，为何半年报计提商誉减值准备-29,933,433.87元？贝达药业回复：您好！伏罗尼布的眼科适应症由公司合作伙伴EyePoint主导开发，8月18日EyePoint对外公布LUGANO研究数据属于资产负债表日后事项，公司于半年报中确认商誉减值，充分关注了期后事项对商誉减值测试结论的影响。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669094671","title":"贝达药业：二季度扣非净利润环比出现波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2669094671","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669094671?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:39","pubTimestamp":1790152746,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司，依据公司公布一季度及半年度财务报告，公司第二季度扣非净利润亏损400万元左右，是什么原因造成的，与一季度相差甚远？是不是以后三，四季度扣非净利润均会亏损？贝达药业回复：您好！二季度扣非净利润环比出现波动，主要受海外商业化推进、学术推广、研发等各项费用投入较高，以及本期计提商誉减值等因素影响。公司经营业绩受产品销售情况、研发投入规模及市场竞争等多重因素影响，敬请关注公司后续披露的定期报告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300028228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668318309","title":"贝达药业最新公告：盐酸恩沙替尼胶囊获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2668318309","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668318309?lang=zh_cn&edition=full","pubTime":"2026-09-20 16:20","pubTimestamp":1789892401,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司控股子公司Xcovery申报的盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局人用药品委员会积极意见，建议批准该药品用于ALK阳性晚期非小细胞肺癌成人患者的治疗。欧盟委员会将基于该积极意见作出最终决定，上市许可申请能否获批尚存在不确定性。恩沙替尼是一种新一代ALK抑制剂，此前已在中国、美国及澳门获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000004134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790648420760,"stockEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":-0.0562},{"period":"3month","weight":-0.2668},{"period":"6month","weight":0.0433},{"period":"1year","weight":-0.2941},{"period":"ytd","weight":0.025}],"compareEarnings":[{"period":"1week","weight":-0.032},{"period":"1month","weight":-0.0325},{"period":"3month","weight":-0.0661},{"period":"6month","weight":-0.0316},{"period":"1year","weight":-0.0012},{"period":"ytd","weight":-0.0366}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"50981人(较上一季度增加19.47%)","perCapita":"8281股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42333万元","survey":" 贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}